A new popliteal DVT makes the kidney-biopsy decision more than a question of naming the lesion. Percutaneous biopsy carries bleeding risk. If anticoagulation has been started for the DVT, biopsy may require an individualized plan for interruption while thrombotic risk remains high. If an adult with nephrotic syndrome has a positive anti-PLA2R result, when is serology enough—and when could tissue still change care?
Consider a 54-year-old man with generalized edema, serum albumin of 21 g/L, heavy proteinuria, a bland urine sediment, and a confirmed popliteal DVT. Now add a positive anti-PLA2R antibody result. Before labeling biopsy either mandatory or unnecessary, retrieve the creatinine and eGFR trajectory, check for diabetes and atypical urine findings, review medications, and assess for possible associated conditions. Those details determine whether the biopsy-sparing pathway fits.
Ask what a biopsy would add
KDIGO states that a kidney biopsy is not required to confirm membranous nephropathy (MN) in a patient with nephrotic syndrome and a positive anti-PLA2R antibody test. This is a diagnostic exception to the familiar rule that unexplained adult nephrotic syndrome often warrants tissue diagnosis. It is not a blanket instruction to avoid biopsy whenever the antibody is positive.
The evidence for deferring biopsy is strongest in adults with preserved, stable kidney function and no diabetes or evidence of an associated disease. In a multicenter validation study, biopsy did not reveal findings that changed diagnosis or management in the selected patients with preserved eGFR, positive serology, and no associated conditions or diabetes. A separate patient with reduced eGFR had additional interstitial nephritis—an example of why kidney function changes the value of tissue.
| Clinical pattern | What positive anti-PLA2R supports | How to think about biopsy |
|---|---|---|
| Nephrotic syndrome, positive result on a validated assay, stable preserved eGFR, bland sediment, and no diabetes or associated cause found | A clinical diagnosis of MN | Biopsy may be deferred if its only purpose would be to confirm MN. |
| Positive result with falling eGFR, acute kidney injury, substantial hematuria or casts, diabetes, or a suspected associated disease | MN may be present, but it may not explain every kidney finding | Tissue may identify a second or alternative process and change treatment or prognosis. |
| Negative anti-PLA2R result or a positive antibody to a different antigen | Does not establish the same biopsy-sparing pathway | A negative PLA2R result does not exclude MN; evaluate the unexplained nephrotic syndrome on its merits. |
The preserved-eGFR cutoff used in studies is a guide to where the evidence is strongest, not a substitute for clinical judgment. Compare current kidney function with prior results rather than treating one creatinine value as a trajectory.
Serology does not replace the secondary-cause review
A positive anti-PLA2R result helps identify PLA2R-associated MN; it does not cancel the evaluation for conditions that may be associated with MN or explain a coexisting illness. Take a medication history, including NSAID use; look for autoimmune or infectious clues; and pursue age-appropriate cancer screening and targeted testing based on the history and examination.
Nor does a positive result alone decide whether immunosuppression is indicated. That decision requires assessment of the kidney-function trend, degree and persistence of proteinuria, serum albumin, antibody levels when appropriate, complications, and the patient’s course. The antibody can help establish the diagnosis without tissue; it is not a stand-alone treatment order.
A negative anti-PLA2R result should not be used to rule MN out. The test is not positive in every patient with MN, so unexplained nephrotic syndrome may still need biopsy. Anti-THSD7A positivity should not automatically be treated as an equivalent biopsy-free diagnostic test; the evidence supporting that approach is not the same.
Let the DVT raise the threshold for low-value biopsy—not forbid useful tissue
In this case, the DVT creates competing risks. A renal biopsy may cause bleeding, and percutaneous biopsy commonly requires individualized anticoagulation planning. If he is anticoagulated, a recent clot makes interruption a high-stakes decision; proceeding without a procedure-specific plan is not a reasonable shortcut either.
The practical question is whether histology is likely to change the next decision. If kidney function is stable and preserved, the urine sediment is bland, diabetes and associated causes have been assessed, and the antibody result is convincing, biopsy solely to confirm MN may add little. If kidney function is worsening, the sediment is atypical, or another diagnosis remains plausible, discuss the expected value and timing of biopsy with nephrology and the team managing the DVT and any anticoagulation. Do not stop or continue anticoagulation around the procedure by reflex.
Common traps are treating biopsy as mandatory for every adult with nephrotic syndrome, treating any positive anti-PLA2R result as a reason never to biopsy, and assuming the DVT itself either requires or rules out tissue. The better question is simpler: What uncertainty would the biopsy resolve, and would resolving it change care?
Practical takeaways
- In an adult with nephrotic syndrome and positive anti-PLA2R, biopsy is not required solely to confirm MN in an appropriate clinical setting.
- Check the eGFR trend, urine sediment, diabetes history, medications, and possible associated causes before applying that pathway.
- Consider biopsy when findings are atypical or tissue could change diagnosis, prognosis, or treatment.
- With a recent DVT, coordinate any biopsy and anticoagulation plan rather than treating either risk in isolation.
